At a glance
ClinicalIndex Comparison RecordN/ACompleted· 674 enrolled
Drug / intervention
Twynsta tabletdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
In Brief
An observational study evaluating Twynsta tablet for Hypertension. Completed, enrolled 674 participants across 1 site.
Detailed Summary
This is a prospective, observational, open-label, multi-center study, which will provide detailed information about the safety and efficacy of Twynsta tablets in Korean hypertensive patients requiring combination therapy. This will present a convenient treatment option for hypertension in Korean patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartDec 2010
Primary CompletionJun 2016
Study CompletionAug 2016
TodayJul 2026
First PostedNov 18, 2010
Enrollment StartDec 21, 2010
Primary CompletionJun 27, 2016
Study CompletionAug 18, 2016
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 15.6 years ago
Interventions
Twynsta tabletdrug
Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10